Literature DB >> 2178330

Effects of treatment on long-term survivors with malignant astrocytomas.

J P Imperato1, N A Paleologos, N A Vick.   

Abstract

We reviewed the records of 160 consecutive patients with glioblastoma and anaplastic astrocytoma to evaluate the long-term consequences of radiation therapy and chemotherapy. We defined long-term survivors as those patients with glioblastoma or anaplastic astrocytoma who lived at least 100% longer than median survival of historical controls, for example, 2 years for patients with glioblastoma and 4 years for patients with anaplastic astrocytoma. There were 9 (5.6%) long-term survivors. Three (30%) became demented and died without evidence of tumor recurrence. One, after survival of 10 years, died of tumor recurrence. Of the remaining survivors, 2 (22%) have significantly impaired short-term memory function and other neurological deficits such as gait apraxia. Three (30%) can function independently. It is likely but cannot be proved that it is radiotherapy and not chemotherapy that is the causal factor of this dismal therapeutic outcome. Our study suggests restraint in the use of radiotherapy for patients with brain tumors that have more favorable prognoses than glioblastomas and anaplastic astrocytomas, such as low-grade astrocytomas and oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178330     DOI: 10.1002/ana.410280614

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  81 in total

1.  Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour.

Authors:  A R Giovagnoli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study.

Authors:  M C Vigliani; C Duyckaerts; J J Hauw; M Poisson; H Magdelenat; J Y Delattre
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

4.  Radiation change versus recurrent astrocytoma: diagnostic utility of the proliferation index?

Authors:  E H Bigio; S M Colvin; B E Mickey; C L White; E J Rushing
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

5.  Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood.

Authors:  Albert Attia; Stephen R Rapp; L Doug Case; Ralph D'Agostino; Glenn Lesser; Michelle Naughton; Kevin McMullen; Robin Rosdhal; Edward G Shaw
Journal:  J Neurooncol       Date:  2012-06-15       Impact factor: 4.130

6.  The use of a simple Likert scale to measure quality of life in brain tumor patients.

Authors:  M P Rogers; J Orav; P M Black
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

7.  Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.

Authors:  Kelly M Macarthur; Gary D Kao; Sanjay Chandrasekaran; Michelle Alonso-Basanta; Christina Chapman; Robert A Lustig; E Paul Wileyto; Stephen M Hahn; Jay F Dorsey
Journal:  Cancer Res       Date:  2014-02-13       Impact factor: 12.701

8.  Early-delayed, radiation-induced cognitive deficits in adult rats are heterogeneous and age-dependent.

Authors:  M E Forbes; M Paitsel; J D Bourland; D R Riddle
Journal:  Radiat Res       Date:  2014-06-17       Impact factor: 2.841

9.  Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Authors:  Bryan D Choi; Chien-Tsun Kuan; Mingqing Cai; Gary E Archer; Duane A Mitchell; Patrick C Gedeon; Luis Sanchez-Perez; Ira Pastan; Darell D Bigner; John H Sampson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

10.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.